Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Melissa Blume

Physician Assistant Litchfield, IL Physician Assistant

NPI 1477865202 CMS profile 10538216

1285 Franciscan Dr, Litchfield, IL 62056

Open in the dashboard

General payments

$3,137

170 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melissa Blume of Litchfield, IL is reported in the CMS Open Payments database as having received $3,137 across 170 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $806 44
2024 General $729 39
2023 General $1,105 59
2022 General $460 25
2021 General $37 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melissa Blume
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Melissa Blume were reported at $806. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Melissa Blume Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $37 $132 $37–$438 $132
2022 $460 $155 $48–$522 $149
2023 $1,105 $167 $52–$557 $160
2024 $729 $178 $55–$600 $164
2025 $806 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $552 31 payments
  2. Lilly USA, LLC $431 21 payments
  3. Novo Nordisk Inc $318 19 payments
  4. Amgen Inc. $232 14 payments
  5. Otsuka America Pharmaceutical, Inc. $189 10 payments
  6. Abbott Laboratories $180 9 payments
  7. Corcept Therapeutics $155 8 payments
  8. Neurocrine Biosciences, Inc. $152 6 payments
  9. Pfizer Inc. $145 8 payments
  10. GlaxoSmithKline, LLC. $101 6 payments
  11. Other $680 38 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,137 170 payments
Products named General payments · program years 2021–2025
  1. MOUNJARO $373 17 payments
  2. QULIPTA $222 10 payments
  3. VRAYLAR $210 13 payments
  4. TRULICITY $205 9 payments
  5. Ozempic $197 12 payments
  6. UBRELVY $195 11 payments
  7. Otezla $182 11 payments
  8. REXULTI $169 9 payments
  9. Repatha $167 10 payments
  10. RYBELSUS $163 10 payments
  11. Other $2,246 122 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 104 drugs

Part D claims

3,987

Median for Physician Assistant: 241

Drug cost

$371,017

Median for Physician Assistant: $4,110

Branded share of claims

29.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 71 $52,884
Mounjaro Tirzepatide Brand 43 $47,776
Trulicity Dulaglutide Brand 44 $44,596
Farxiga Dapagliflozin Propanediol Brand 29 $22,689
Jardiance Empagliflozin Brand 29 $21,826
Ozempic Semaglutide Brand 23 $21,481
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 42 $17,942
Breo Ellipta Fluticasone/Vilanterol Brand 38 $15,100
Rybelsus Semaglutide Brand 14 $14,835
Aimovig Autoinjector Erenumab-Aooe Brand 13 $9,720

The 10 drugs with the highest cost, of 104 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $67
$67 43 —
RYBELSUS
  • Novo Nordisk Inc $56
$56 14 —
Ozempic
  • Novo Nordisk Inc $56
$56 23 —
UBRELVY
  • AbbVie, Inc. $34
$34 — —
QULIPTA
  • AbbVie, Inc. $34
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

170 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record